Recurrent and metastatic endometrial cancer

The prognosis for patients with recurrent or metastatic endometrial cancer has historically been poor, with a 5-year survival rate of only 20-25%. Traditional treatment approaches, such as chemotherapy and hormonal treatments, have had limited clinical success. However, advances in the molecular classification of these tumors have revolutionized treatment approaches by enabling precise prognostic evaluations and the development of targeted therapies, which have significantly improved outcomes, particularly in advanced stages. To facilitate personalized treatment, molecular analyses should ideally be conducted at the time of initial diagnosis. Treatment decisions should always be made within an interdisciplinary framework, taking into account the patient's preferences, general condition, disease extent, and prior treatments. In conclusion, advances in tumor biology and the development of innovative treatments have markedly improved the prognosis of patients with advanced endometrial cancer. Nonetheless, further research, particularly prospective studies focusing on long-term outcomes and side effect management, are essential to optimize care and refine treatment strategies.